Kodiak Sciences stock clears a major clinical hurdle

Kodiak Sciences reported that Zenkuda and KSI-501 met the primary endpoints in the Phase 3 DAYBREAK trial on September 28, 2026, giving the precommercial biotechnology company a major clinical milestone. According to Kodiak Sciences, both investigational therapies achieved non-inferior vision gains against aflibercept at one year.

DAYBREAK delivers measurable progress

Zenkuda, also known as tarcocimab tedromer, reached six-month dosing durability for 54 percent of patients at one year under strict treat-to-dryness retreatment criteria. The treatment recorded a 0.5 percent cataract adverse-event rate versus 0.9 percent for aflibercept, while the company reported a 0 percent intraocular inflammation rate.

The second candidate, tabirafusp-ted, met its vision primary endpoint and an anatomical key secondary endpoint. Kodiak Sciences said it plans to submit Zenkuda data to regulators in the fourth quarter of 2026 based on five positive Phase 3 studies.

Losses keep the valuation demanding

The clinical progress is set against continuing operating losses. MarketBeat reported that Kodiak posted quarterly EPS of minus USD 1.05 for the period released on August 13, 2026, compared with a consensus loss of USD 0.96. HC Wainwright also cut its fiscal 2027 loss estimate to USD 3.36 per share from USD 3.27 while retaining a Buy rating and a USD 96.00 price target.

Cash remains a central commercial consideration as Kodiak advances toward regulatory submissions. 24/7 Wall St. reported that cash declined from USD 209.9 million at year-end 2025 to USD 125.9 million by mid-2026, while quarterly net losses ranged from USD 56.7 million to USD 65.6 million over the last four quarters.

Market value reaches USD 5.9 billion

Kodiak Sciences had a market capitalization of USD 5.9 billion as of September 30, 2026. Its 52-week range was USD 10.94 to USD 98.80, leaving the valuation closely tied to the regulatory path for Zenkuda and the next clinical milestones.